Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

Impact · against what's priced in

Alkermes is positioned for growth through the strategic acquisition of Avadel and positive Phase 2 data for alixorexton. The combination of immediate revenue momentum from LUMRYZ and pipeline expansion provides a clear catalyst for valuation increase.

ALKS+0.60: No priced-in read yet
In context: The combination of positive phase 2 data for alixorexton and the accretive acquisition of Avadel's LUMRYZ provides both immediate revenue momentum and future pipeline growth.
Read from the article alone

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

biotech
ALKS
AVDL
acquisition
clinical trials
drug development
narcolepsy
pharma
pipeline

Search tags

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What matters in this story

Small Cap Watch: Actinogen locks XanaMIA database and Kingfisher advances Broken Hill portfolio

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What matters in this story

Small Cap Watch: Actinogen locks XanaMIA database and Kingfisher advances Broken Hill portfolio

How each ticker is affected

Connected tickers

Track these names every morning.

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher

OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What matters in this story

Next reads from the same story arc

Small Cap Watch: Actinogen locks XanaMIA database and Kingfisher advances Broken Hill portfolio

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

What matters in this story

Next reads from the same story arc

Small Cap Watch: Actinogen locks XanaMIA database and Kingfisher advances Broken Hill portfolio

How each ticker is affected

Connected tickers

Track these names every morning.

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher

OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites